1. Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

3. Introduction/Background

4. Unmet Needs in Pediatric Type 1 Diabetes

5. PPG, HbA1c, and Risk Factor Exacerbation

6. Hypoglycemia and the Pediatric T1DM Patients

7. Recommended Targets for PPG: Association Guidelines

8. Post-Meal Dosing of Prandial Insulin Associated With Poorer Glycemic Control

9. Pharmacokinetic Action Profiles of Insulin Replacement Therapy

10. Faster-Acting Insulin: Approaching a More Exact Physiological Insulin Profile

11. Designing an Ultra-Fast Acting Insulin

12. 994-P/ Ultra-Rapid BioChaperone Lispro (BCLIS) vs Insulin Lispro (LIS): Blood Glucose and PK Parameters

13. Faster Onset of Appearance and Greater Early Exposure With Faster Acting Insulin Aspart vs Insulin Aspart

14. Onset® 1: Postprandial Plasma Glucose (Test Meal)

15. Onset® 1: Severe and Confirmed Hypoglycemia

16. Onset® 4: Incidence of Hyperglycemia

17. Onset® 5: PPG Increment Results After a Standardized Meal Test

18. Onset®7: Trial Design

19. Onset®7: Mean HbA1c Over Time: Mealtime and Postmeal Comparisons

20. Onset®7: Change in HbA1c From Baseline Was Independent of Age

21. Onset®7: Mean 1-Hour PPG at Week 26: Based on 8-Point SMBG Profiles

22. Onset®7: Treatment-Emergent Hypoglycemia After 26 Weeks

23. Conclusions: Onset®7

24. Summary and Conclusions

25. Abbreviations

26. Abbreviations (cont)